Mesenchymal stromal cell-derived extracellular vesicles: engineering strategies and bioprocess controls for scalable and reproducible therapeutics

Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics because of their immunomodulatory and regenerative potential. Yet their clinical translation remains constrained by a persistent gap between functional optimization and manufacturing control. Low production yield, substantial heterogeneity, limited cargo control, and inadequate process standardization continue to compromise reproducibility, cross-study comparability, and scalable development. As a result, improvements in functional performance have not been matched by equivalent advances in product consistency and clinical manufacturability. This review discusses how exogenous conditioning, endogenous engineering, and bioprocess design can be leveraged to improve both MSC-EV function and translational feasibility. We assess current approaches to enhancing MSC-EV production and therapeutic activity, including priming strategies, genetic modification, and scalable culture systems, with emphasis on their benefits, limitations, and clinical relevance. We also examine critical translational barriers, including inconsistent isolation and quantification methods, the lack of standardized potency assays, and ill-defined critical quality attributes. Future progress in MSC-EV therapeutics will depend not simply on improving efficacy, but on establishing integrated development frameworks that align functional optimization with controllable risk, traceable quality, and affordable cost.